ProQR Therapeutics N.V.
PRQR
$1.62
$0.0754.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.59M | 4.22M | 6.79M | 4.83M | 3.54M |
| Total Other Revenue | 145.00K | 151.70K | 167.90K | 228.00K | 0.00 |
| Total Revenue | 4.74M | 4.38M | 6.95M | 5.06M | 3.54M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4.74M | 4.38M | 6.95M | 5.06M | 3.54M |
| SG&A Expenses | 4.17M | 3.61M | 3.24M | 3.75M | 5.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.48M | 13.96M | 10.83M | 13.82M | 13.44M |
| Operating Income | -10.75M | -9.58M | -3.87M | -8.77M | -9.90M |
| Income Before Tax | -9.92M | -8.91M | -3.11M | -8.31M | -5.90M |
| Income Tax Expenses | 0.00 | -- | -215.30K | 3.30K | 5.40K |
| Earnings from Continuing Operations | -9.92M | -8.91M | -2.90M | -8.31M | -5.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 0.00 |
| Net Income | -9.92M | -8.91M | -2.90M | -8.31M | -5.90M |
| EBIT | -10.75M | -9.58M | -3.87M | -8.77M | -9.90M |
| EBITDA | -10.51M | -8.83M | -3.11M | -8.02M | -9.72M |
| EPS Basic | -0.10 | -0.11 | -0.04 | -0.10 | -0.07 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.02 | -0.06 | -0.07 |
| EPS Diluted | -0.10 | -0.11 | -0.04 | -0.10 | -0.07 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.02 | -0.06 | -0.07 |
| Average Basic Shares Outstanding | 99.43M | 81.68M | 81.67M | 81.57M | 81.22M |
| Average Diluted Shares Outstanding | 99.43M | 81.68M | 81.67M | 81.57M | 81.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |